MMEL1

Across TCGA pan-cancer cohorts, MMEL1 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated MMEL1 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher MMEL1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated MMEL1 expression acts as an unfavorable survival marker.

DLBC, LIHC, and PRAD are the cancer types where MMEL1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	DFS	Median	II,III,IV	0.065	0.829	<.001	24	view →
LIHC	DFS	Median	All	0.080	0.553	.004	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
STAD	DFS	Median	All	0.251	0.562	.026	6	view →
HNSC	OS	Median	All	0.454	0.771	.018	4	view →
GBM	DFS	Median	All	0.031	0.243	<.001	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

MMEL1–DLBC (DFS)

Open the DLBC breakdown →